Welcome to our dedicated page for BRUKP SEC filings (Ticker: BRUKP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BRUKP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BRUKP's regulatory disclosures and financial reporting.
Bruker Corp executive Mark Munch reported option exercises and a share sale. On February 13, he exercised stock options for 2,000 shares, converting derivative securities into common stock at a price of $22.19 per share. He then sold 2,000 common shares at $36.94 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan.
Following these transactions, he directly owned 128,443 shares of Bruker common stock and held 14,000 stock options.
BRUKER CORP director Bonnie H. Anderson reported an equity award of 4,520 shares of Common Stock. The award was made at a price of $0.00 per share as a grant or other acquisition. Following this award, she reports beneficial ownership of 17,847 Common Stock shares.
According to the filing, the grant is in the form of Restricted Stock Units that will vest in a single installment on February 15, 2027. On that vesting date, each RSU will automatically convert into an equal number of shares of Bruker common stock.
Bruker Corp received an updated ownership report showing that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, and Orbis Investment Management (U.S.) L.P. together beneficially own 14,906,730 shares of Bruker common stock, representing 9.8% of the outstanding class.
Orbis Investment Management Ltd reports sole voting and dispositive power over 14,077,895 shares, Allan Gray Australia over 22,092 shares, and Orbis Investment Management (U.S.) L.P. over 806,743 shares. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Bruker.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of 4,594,398 shares of Bruker Corp common stock, representing 3.0% of the class as of 12/31/2025. The firm has sole voting power over 4,584,656 shares and sole dispositive power over 4,594,398 shares, with no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Bruker. The filer also affirms that this should not be construed as an admission of beneficial ownership, which is expressly denied.
A holder of BRKR common stock has filed a notice to sell 2,000 shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $73,880. The shares are listed on NASDAQ, and the filing states 151,941,144 shares of this class are outstanding.
The 2,000 shares to be sold were acquired on 02/13/2026 via a stock option exercise from the issuer, paid in cash the same day. The person named in recent activity, Mark R. Munch, has already sold common shares in the past three months, including 2,000 shares on 01/15/2026 for $98,400, 7,000 shares on 01/12/2026 for $385,000, and 33,843 shares on 01/05/2026 for $1,680,704.
Bruker Corporation reported a challenging 2025, with modest growth but weaker profitability and a GAAP loss. Full-year revenue rose to $3.44 billion, up 2.1% from 2024, yet organic revenue fell 3.7%. Q4-25 revenue was $977.2 million, essentially flat year-over-year.
GAAP operating income dropped to $68.2 million for 2025 from $253.1 million, driven by $127.2 million of goodwill and intangible impairments and $77.4 million of restructuring charges. GAAP diluted loss per share was $(0.15), while non-GAAP diluted EPS was $1.83, down from $2.41.
Management initiated 2026 guidance calling for revenue of $3.57–$3.60 billion, implying 4%–5% growth, with 1%–2% organic growth and non-GAAP EPS of $2.10–$2.15, 15%–17% above 2025 despite an estimated 8% foreign-exchange headwind.